

1. Record Nr.	UNINA9910819963703321
Autore	Jacobs Charlotte
Titolo	Jonas Salk : a life // Charlotte DeCroes Jacobs
Pubbl/distr/stampa	New York, New York : , : Oxford University Press, , [2015] ©2015
ISBN	0-19-933443-9 0-19-933442-0
Descrizione fisica	1 online resource (572 p.)
Classificazione	MED022000SCI034000MED039000
Disciplina	579.2092 B
Soggetti	Virologists - United States Poliomyelitis - United States - History Poliomyelitis - Vaccination - United States - History Poliomyelitis vaccine - History Influenza vaccines - History AIDS vaccines
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Cover; Jonas Salk: A Life; Copyright; Dedication; Epigraph; Contents; Prologue: Two Plagues; Chapter 1: Born to Serve; Chapter 2: Finding His Place; Chapter 3: A Wedding and a War; Chapter 4: Joining the Fight Against Influenza; Chapter 5: Vaccine Neophyte; Chapter 6: Pittsburgh's Virgin Territory; Chapter 7: Polio; Chapter 8: The Chosen; Chapter 9: Ready to Run; Chapter 10: Research Sub Rosa; Chapter 11: Out of His Hands; Chapter 12: The World's Largest Clinical Trial; Chapter 13: Relief from Fear; Chapter 14: The Cutter Affair; Chapter 15: Fame and Its Consequences; Chapter 16: Act II Chapter 17: Two Cultures Under One RoofChapter 18: The Price of a Masterpiece; Chapter 19: Seeking Shangri-La; Chapter 20: A Troubled Marriage; Chapter 21: Harnessing the Immune System; Chapter 22: A Most Unusual Arrangement; Chapter 23: Salk Unfolding; Chapter 24: Fall from Grace; Chapter 25: Final fling; Chapter 26: Marginalized; Chapter 27: The Swine Flu Snafu; Chapter 28: Return to the Polio

Vaccine Controversy; Chapter 29: A Trojan Horse; Chapter 30: Disciples, Sycophants, and Lovers; Chapter 31: AIDS: Salk's Next Mountain; chapter 32: Unbowed; Acknowledgments; Notes; Abbreviations
PrologueChapter 1; Chapter 2; Chapter 3; Chapter 4; Chapter 5; Chapter 6; Chapter 7; Chapter 8; Chapter 9; Chapter 10; Chapter 11; Chapter 12; Chapter 13; Chapter 14; Chapter 15; Chapter 16; Chapter 17; Chapter 18; Chapter 19; Chapter 20; Chapter 21; Chapter 22; Chapter 23; Chapter 24; Chapter 25; Chapter 26; Chapter 27; Chapter 28; Chapter 29; Chapter 30; Chapter 31; Chapter 32; Bibliography; Manuscript Collections; Books and Journal Articles; Author's Interviews; Index

Sommario/riassunto

"When a waiting world learned on April 12, 1955, that Jonas Salk had successfully created a vaccine to prevent poliomyelitis, he became a hero overnight. Born in a New York tenement, humble in manner, Salk had all the makings of a twentieth-century icon—a knight in a white coat. In the wake of his achievement, he received a staggering number of awards and honors; for years his name ranked with Gandhi and Churchill on lists of the most revered people. And yet the one group whose adulation he craved—the scientific community—remained ominously silent. "The worst tragedy that could have befallen me was my success," Salk later said. "I knew right away that I was through—cast out." In the first complete biography of Jonas Salk, Charlotte DeCroses Jacobs unravels Salk's story to reveal an unconventional scientist and a misunderstood and vulnerable man. Despite his incredible success in developing the polio vaccine, Salk was ostracized by his fellow scientists, who accused him of failing to give proper credit to other researchers and scorned his taste for media attention. Even before success catapulted him into the limelight, Salk was an inscrutable man disliked by many of his peers. Driven by an intense desire to aid mankind, he was initially oblivious and eventually resigned to the personal cost—as well as the costs suffered by his family and friends. And yet Salk remained, in the eyes of the public, an adored hero. Based on hundreds of personal interviews and unprecedented access to Salk's sealed archives, Jacobs' biography offers the most complete picture of this complicated figure. Salk's story has never been fully told; until now, his role in preventing polio has overshadowed his part in co-developing the first influenza vaccine, his effort to meld the sciences and humanities in the magnificent Salk Institute, and his pioneering work on AIDS. A vivid and intimate portrait, this will become the standard work on the remarkable life of Jonas Salk"--

2. Record Nr.	UNINA9911004716203321
Titolo	Approaches to risk management in remediation of radioactively contaminated sites [[electronic resource]]
Pubbl/distr/stampa	Bethesda, MD, : National Council on Radiation Protection and Measurement, c2004
ISBN	1-4294-7992-2 1-60119-211-8
Descrizione fisica	1 online resource (291 p.)
Collana	NCRP report ; ; no. 146
Disciplina	363.72/89
Soggetti	Radioactive waste sites - Risk assessment Risk management
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	"Recommendations of the National Council on Radiation Protection and Measurements; issued October 15, 2004."
Nota di bibliografia	Includes bibliographical references (p. 238-256) and index.
Nota di contenuto	""Cover""; ""Preface""; ""Contents""; ""Executive Summary""; ""Extended Summary""; ""1. Introduction""; ""1.1 Purpose and Scope""; ""1.2 NCRP Process""; ""1.3 Outline of the Report""; ""2. Current Regulatory Guidance and Practice""; ""2.1 Principal Governing Laws and Organizational Structure""; ""2.1.1 Governing Laws and Organizational Structure of NRC""; ""2.1.2 Governing Laws and Organizational Structure of EPA""; ""2.1.3 Relationships Between NRC or EPA and the States""; ""2.2 Regulations for Remediation of Radioactively Contaminated Sites""; ""2.2.1 NRC Regulations"" ""2.2.2 EPA Regulations""""2.2.3 Comparison of NRC and EPA Regulations""; ""2.2.4 Decision Process in Decommissioning of Contaminated Sites""; ""2.2.5 Role of States in Remediation of Licensed Facilities""; ""2.2.6 Resource Conservation and Recovery Act Impact on Radioactively Contaminated Sites""; ""2.3 Methods of Site Characterization and Dose or Risk Assessment""; ""2.3.1 EPA Calculation Methods""; ""2.3.2 NRC Calculation Methods""; ""2.3.3 DOE Methods: The Residual Radiation (RESRAD) Family of Codes""; ""3. Analysis of Regulatory Guidance and Practice"" ""3.1 Principal Governing Laws and Organizational Structures""""3.1.1 Differences in Governing Laws""; ""3.1.2 Commonalities in Governing

Laws"; "3.1.3 Organizational Structures and Functions"; "3.2 Regulations for Remediation of Radioactively Contaminated Sites"; "3.2.1 Different Approaches to Regulation by NRC and EPA"; "3.2.2 Commonalities in Approaches to Regulation by NRC and EPA"; "3.2.3 Comparison of NRC and EPA Remediation Standards"; "3.2.4 Discussion of Origins of Different Approaches to Regulation"; "3.3 Methods of Site Characterization and Dose or Risk Assessment" "3.3.1 Methods of Site Characterization and Verification" "3.3.2 Methods of Dose or Risk Assessment"; "3.3.3 Comparison of EPA Preliminary Remediation Goals with NRC Screening Levels"; "3.3.4 Analysis of 239Pu Remediation Levels for 10 Cases"; "3.3.5 Uncertainties in Assessments of Dose or Risk at Contaminated Sites"; "4. Practical Decision Making at Specific Sites"; "4.1 Discussion of Case Studies"; "4.1.1 Fernald and Rocky Flats: End-Use Considerations"; "4.1.2 West Valley Demonstration Project: Multiple Regulation of a Complex Site" "4.1.3 The Johns Hopkins and the Environmental Law Institute Study" "4.1.4 Paducah, Brookhaven and Fernald: The Importance of Trust"; "4.1.5 Case Studies by the Interstate Technology and Regulatory Council"; "4.1.6 Observations on Practical Remediations"; "4.2 Recurrent Themes Observed in the Case Studies"; "4.2.1 Assumptions About Future Use of Sites, as Well as Assessments of Off-Site Risks, Drive Risk Management Decision Making"; "4.2.2 Public Participation, Input and Acceptance are Critical for Successful Risk Management"; "4.2.3 Distributive and Procedural Fairness" "4.2.4 Various Approaches are Used Across Sites to Assess and Manage Risks"
